<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02793661</url>
  </required_header>
  <id_info>
    <org_study_id>REN-01</org_study_id>
    <nct_id>NCT02793661</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Use of RenalGuard to Protect Patients at High Risk of AKI</brief_title>
  <acronym>STRENGTH</acronym>
  <official_title>Study to Evaluate the Use of RenalGuard to Protect Patients at High Risk of AKI (STRENGTH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Cardiovascular Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RenalGuard Solutions, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Cardiovascular Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Strength study aim to evaluate the use of the RenalGuard device to protect the patients
      at high risk to develop acute kidney injury following a complex cardiovascular intervention
      requiring a high volume of contrast.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Strength Trial is a randomized, international (France and Germany) and multicentre (7)
      trial.

      The patients population targeted is suffering from kidney insufficiency (estimated Glomerular
      Filtration Rate (eGFR) between 15 to 40 ml/min/m2) need to go through a complex
      cardiovascular intervention..

      This is a population of patients at high risk to develop AKI following contrast media
      administration and complex cardiovascular interventions require a high amount of contrast.

      Standard treatment is hydration but with risk of hyper and hypohydration for this population
      of patients. RenalGuard insure the replacement of the urine output by infusion of a matched
      volume of sterile replacement solution to maintain patients' intravascular fluid volume.

      The patients are randomized to be protected from contrast-induced nephropathy with the use of
      RenalGuard or by standard hydration treatment and will be followed-up during 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of contrast-induced nephropathy</measure>
    <time_frame>Within 5 days</time_frame>
    <description>The occurence of contrast-induced nephropathy will be determined:
by an elevation, within 3 days from requiring contrast-procedure, of the serum creatinine (rise of 0.3mg/dl or of 25% compared to basal value) and/or
by the need for dialysis within 5 fays from requiring contrast-procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum creatinin value</measure>
    <time_frame>at 12 +-1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the estimated glomerular filtration rate</measure>
    <time_frame>at 12 +-1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients on chronic dialysis</measure>
    <time_frame>at 12 +-1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients on temporary dialysis</measure>
    <time_frame>at 12 +-1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In hospital significant urinary bleeding, infection or any other major complication cause by the urinary catheter</measure>
    <time_frame>within 5 days from procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of major adverse cardiovascular and cerebrovascular events (death, myocardial infarction, stroke, revascularization)</measure>
    <time_frame>at 12 +-1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual MACCEs components (death, myocardial infarction, stroke, revascularization)</measure>
    <time_frame>at 12 +-1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic evaluation of RenalGuard compared to standard renal protection according to ESC guidelines</measure>
    <time_frame>Index hospitalization (including staged procedures) and 12+- 1 months</time_frame>
    <description>cost utility analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>RenalGuard Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In order to prevent patients from acute kidney injury, patients will receive the RenalGuard Therapy delivered by the RenalGuard system from one hour before the cardiovascular intervention to 4 hours after the intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will received standard treatment, as per ESC Guidelines 2014, to prevent from acute kidney injury.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RenalGuard</intervention_name>
    <description>Replacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient's intravascular fluid volume. Diuretic is administered to reach an optimum urine flow and protect efficiently the patients' kidneys.</description>
    <arm_group_label>RenalGuard Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Hydration protocol following ESC Guidelines 2014</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old

          -  15 ml/min/m2 ≤ eGFR ≤ 40 ml/min/m2

          -  High volume contrast-requiring cardiovascular procedures (estimated contrast volume &gt;
             3 times eGFR value)

          -  Patient has agreed to all FU testing

        Exclusion Criteria:

          -  Administration of iodine contrast media within 5 days before index procedure

          -  Emergency procedure or primary PCI

          -  Patients with pulmonary edema or cardiogenic shock (Killip 3 or 4)

          -  Hypoxemia defined as SaO2 ≤ 90% and/or PaO2 ≤ 80 mmHg on room air

          -  Acute Kidney Injury requiring dialysis before the procedure

          -  Multiple myeloma or cancer treated with chemotherapy

          -  Subjet is anuric

          -  Subject has been hospitalized for any change in renal function or has undergone renal
             replacement therapy (hemodialysis or hemofiltration) within the past month

          -  Known hypersensitivity to furosemide active ingredient or excipient

          -  Renal insufficiency with oligoanuria resistant to furosemide or caused by nephrotoxic
             or hepatotoxic substances

          -  Pre-coma or coma induced by an hepatic encephalopathy

          -  Severe hypokalemia, sever hyponatremia, hypovolemia with or without hypotension or
             dehydration

          -  Hypersensitivity to sulfamides

          -  Enrollment in another study unless the study is a registry or unless primary endpoint
             is reached

          -  Expected life expectancy &lt; 1 year

          -  Pregnant or breastfeeding patient

          -  Patient under trusteeship or guardianship

          -  Patient is unable / unwilling to provide an informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Halpert</last_name>
    <role>Study Director</role>
    <affiliation>RenalGuard Solutions, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Heringer, PhD</last_name>
    <phone>+33 (0)1 76 73 92 16</phone>
    <email>jheringer@cerc-europe.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laure Morsiani, Ph D</last_name>
    <phone>+33 (0)1 76 73 92 36</phone>
    <email>lmorsiani@cerc-europe.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Privé Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Garot</last_name>
      <phone>+33160134602</phone>
      <email>pgarot@angio-icps.com</email>
    </contact>
    <investigator>
      <last_name>Philippe Garot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Claude Galien</name>
      <address>
        <city>Quincy-sous-sénart</city>
        <zip>91480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Garot</last_name>
      <phone>+33169399169</phone>
      <email>pgarot@angio-icps.com</email>
    </contact>
    <investigator>
      <last_name>Philippe Garot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Carrié</last_name>
      <email>carrie.didier@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Didier Carrié</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Fajadet</last_name>
      <email>jfajadet@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Jean Fajadet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georg Nickenig</last_name>
      <email>georg.nickenig@ukb.uni-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Georg Nickenig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovasculares Centrum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Horst Sievert</last_name>
      <email>horstsievertmd@aol.com</email>
    </contact>
    <investigator>
      <last_name>Horst Sievert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Josefs Hospital</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Horst Sievert, Prof</last_name>
      <email>horstsievertmd@aol.com</email>
    </contact>
    <investigator>
      <last_name>Horst Sievert, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2016</study_first_submitted>
  <study_first_submitted_qc>June 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2016</study_first_posted>
  <last_update_submitted>September 2, 2016</last_update_submitted>
  <last_update_submitted_qc>September 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

